| Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers (NCT04682847) | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 2020-11-19 |
| MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) (NCT03712280) | Mallinckrodt | 2018-12-01 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (NCT03486912) | Bristol-Myers Squibb | 2018-06-12 |
| A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C (NCT03420768) | Bristol-Myers Squibb | 2018-02-14 |
| A Study of Experimental Medication BMS-986036 Given to Healthy Participants (NCT03445208) | Bristol-Myers Squibb | 2018-02-14 |
| Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis (NCT02652351) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2016-03-01 |
| The Treatment of Hepatocirrhosis and Portal Hypertension (NCT02778425) | Yanjing Gao | 2016-02-01 |
| Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases (NCT02171949) | Hospital Sao Rafael | 2015-04-01 |
| A Study of IDN-6556 in Subjects With Liver Cirrhosis (NCT02230670) | Conatus Pharmaceuticals Inc. | 2014-08-01 |
| A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension (NCT02230683) | Conatus Pharmaceuticals Inc. | 2014-08-01 |
| A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV (NCT02138253) | Conatus Pharmaceuticals Inc. | 2014-05-01 |
| Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites (NCT02163512) | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 2014-03-12 |
| Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites (NCT01349348) | Otsuka Beijing Research Institute | 2010-10-01 |
| Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy (NCT01135628) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2010-08-01 |
| Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites (NCT01349335) | Otsuka Beijing Research Institute | 2009-04-01 |
| Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis (NCT00896597) | Norgine | 2009-04-01 |
| Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis (NCT01359462) | Otsuka Beijing Research Institute | 2009-04-01 |
| Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function (NCT00698464) | Novartis Pharmaceuticals | 2008-07-01 |
| Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity. (NCT00794482) | Norgine | 2008-03-01 |
| Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin (NCT00857480) | Norgine | 2006-06-01 |
| Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers (NCT00856713) | Norgine | 2006-03-01 |
| Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers (NCT00856869) | Norgine | 2004-08-01 |
| Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment (NCT00006164) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2000-06-01 |